Suppr超能文献

多功能金纳米颗粒克服 miRNA 调控网络介导的多药耐药白血病。

Multifunctional Gold Nanoparticles Overcome MicroRNA Regulatory Network Mediated-Multidrug Resistant Leukemia.

机构信息

State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, International Research Center for Chemistry-Medicine Joint Innovation, College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun, 130012, China.

International Joint Research Laboratory of Nano-Micro Architecture Chemistry (NMAC), College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun, 130012, China.

出版信息

Sci Rep. 2019 Mar 29;9(1):5348. doi: 10.1038/s41598-019-41866-y.

Abstract

Resistance to chemotherapy and molecularly targeted therapies is a major problem in current leukemia treatments. Here, we investigated cross-talk between the miR-221 network and P-glycoprotein (P-gp) in doxorubicin-induced drug resistance of leukemia cells. Multifunctional gold nanoparticles were designed and synthesized to co-deliver three anticancer agents, AS1411, doxorubicin and anti-221, for improving leukemia treatment efficacy. These nanoparticles significantly inhibited the proliferation and clonogenic potential, and induced apoptosis of drug-resistant leukemia cells. The decreased growth of drug-resistant cells induced by these nanoparticles was associated with marked downregulation of miR-221 and DNMT1, leading to restored p27kip1 and p15ink4b tumor suppressor expression, as well as miR-221-mediated reduction of P-gp expression. Finally, primary blasts derived from leukemia patients experiencing chemoresistant relapse that were exposed to these nanoparticles were sensitized to doxorubicin, as evidenced by suppression of leukemic cell growth and a significant reduction of the doxorubicin IC50 value. Our findings provide proof of concept that this novel drug delivery system can precisely reverse the multidrug resistant leukemia phenotype based on preclinical models of leukemia, providing the framework for future clinical trials aimed at overcoming drug resistance and improving patient outcome.

摘要

化疗和分子靶向治疗的耐药性是当前白血病治疗的主要问题。在这里,我们研究了 miR-221 网络与多药耐药白血病细胞中 P-糖蛋白(P-gp)之间的相互作用。设计并合成了多功能金纳米粒子,以共同递送三种抗癌药物,即 AS1411、阿霉素和抗 221,以提高白血病治疗效果。这些纳米粒子显著抑制了耐药性白血病细胞的增殖和集落形成能力,并诱导其凋亡。这些纳米粒子引起的耐药细胞生长减少与 miR-221 和 DNMT1 的明显下调有关,导致 p27kip1 和 p15ink4b 肿瘤抑制因子的表达恢复,以及 miR-221 介导的 P-gp 表达减少。最后,暴露于这些纳米粒子的来自经历化疗耐药复发的白血病患者的原始细胞被增敏至阿霉素,这表现在抑制白血病细胞生长和显著降低阿霉素 IC50 值方面。我们的研究结果提供了概念验证,即这种新型药物递送系统可以基于白血病的临床前模型精确逆转多药耐药白血病表型,为旨在克服耐药性和改善患者预后的未来临床试验提供了框架。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验